Delivering immunochemotherapy earlier in advanced non-small cell lung cancer significantly improves survival outcomes, according to findings from a randomized Phase three trial. The LungTIME C01 trial, involving 210 patients with stage IIIC to IV lung cancer, assigned participants to receive treatment either before or after 3 PM.
After nearly three years of follow-up, patients receiving early treatment saw median progression-free survival extend to 11.3 months, compared to 5.7 months for those receiving late treatment. This represented a 60% reduction in the hazard of earlier disease progression. Median overall survival also showed a substantial benefit for early treatment, reaching 28.0 months versus 16.8 months, a 58% reduction in the hazard of death.
Immunological analyses indicated that early administration enhanced anti-tumor CD8-positive T cell activity. Treatment-related adverse events were consistent with established profiles, and no new safety concerns emerged between the early and late treatment groups.
These results suggest that treatment timing is a critical, modifiable factor in optimizing immunochemotherapy for advanced non-small cell lung cancer.